Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review

References

• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685-699.
   Web of Science ®Google Scholar
• Daien C, Hua C, Gaujoux-Viala C, et al. Update of French Society for Rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine. 2019;86:135–150.
   PubMed Web of Science ®Google Scholar
• Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet. 2005;365:82–93.
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.
   PubMed Web of Science ®Google Scholar
• Luttropp K, Dozier M, Justo N, et al. Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review. BMJ Open. 2019;9:e027456.
   PubMed Web of Science ®Google Scholar
• Souto A, Maneiro JR, Gómez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55:523–534.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Belhassen M, Hudry C, et al. Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: an observational study in 8052 patients. Joint Bone Spine. 2020;87:267–269.
   PubMed Web of Science ®Google Scholar
• Strand V, Miller P, Williams SA, et al. Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the corrona RA registry. Rheumatol Ther. 2017;4:489–502.
   PubMed Web of Science ®Google Scholar
• Cho S-K, Sung Y-K, Kim D, et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:333.
   PubMed Web of Science ®Google Scholar
• Wilke T, Mueller S, Lee SC, et al. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. BMC Musculoskelet Disord. 2017;18:332.
   PubMed Web of Science ®Google Scholar
• Pers Y-M, Schaub R, Constant E, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2015;82:25–30.
   PubMed Web of Science ®Google Scholar
• Lauper K, Mongin D, Iannone F, et al. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. Semin Arthritis Rheum. 2020;50:17–24.
   PubMed Web of Science ®Google Scholar
• Neubauer S, Cifaldi M, Mittendorf T, et al. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Econ Rev. 2014;4:32.
   PubMedGoogle Scholar
• Lee J, Mason R, Martin L, et al. Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study. Rheumatol Int. 2014;34:1449–1453.
   PubMed Web of Science ®Google Scholar
• McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British Society for Rheumatology Biologics register. BMC Musculoskelet Disord. 2016;17:337.
   PubMed Web of Science ®Google Scholar
• Choquette D, Bessette L, Alemao E, et al. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry. Arthritis Res Ther. 2019;21:138.
   PubMed Web of Science ®Google Scholar
• Gabay C, Physicians on behalf of the S collaborating, Riek M, et al. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford). 2015;54:1664–1672.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Bíró A, Szekanecz Z, et al. Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. Clinicoecon Outcomes Res. 2017;9:139–147.
   PubMed Web of Science ®Google Scholar
• Cho S-K, Sung Y-K, Choi C-B, et al. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int. 2012;32:3851–3856.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sruamsiri R. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Prefer Adherence. 2016;10:1509–1519.
   PubMed Web of Science ®Google Scholar
• Gomes JL, Sepriano A, Eusébio M, et al. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt. Acta Reumatol Port. 2019;44:57–64.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Landewé R, Van Der Heijde D, et al. Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? RMD Open. 2015;1:e000155.
   PubMed Web of Science ®Google Scholar
• Torrente-Segarra V, Bergstra SA, Solomon-Escoto K, et al. Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients? Scand J Rheumatol. 2018;47:360–363.
   PubMed Web of Science ®Google Scholar
• Söderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1–9.
   PubMed Web of Science ®Google Scholar
• Lauper K, Mongin D, Alpizar-Rodriguez D, et al. Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology (Oxford). 2019;58:2221–2229.
   PubMed Web of Science ®Google Scholar
• Iannone F, Fanizzi R, Notarnicola A, et al. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine. 2015;82:187–191.
   PubMed Web of Science ®Google Scholar
• Frisell T, Saevarsdottir S, Askling J. Does a family history of RA influence the clinical presentation and treatment response in RA? Ann Rheum Dis. 2016;75:1120–1125.
   PubMed Web of Science ®Google Scholar
• Forsblad-d’Elia H, Bengtsson K, Kristensen LE, et al. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology (Oxford). 2015;54:1186–1193.
   PubMed Web of Science ®Google Scholar
• Nüßlein HG, Alten R, Galeazzi M, et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord. 2015;16:176.
   PubMed Web of Science ®Google Scholar
• Oldroyd AGS, Symmons DPM, Sergeant JC, et al. Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018;57:1089–1096.
   PubMed Web of Science ®Google Scholar
• Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43:447–457.
   PubMed Web of Science ®Google Scholar
• Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179–1184.
   PubMed Web of Science ®Google Scholar
• Leffers HC, Ostergaard M, Glintborg B, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011;70:1216–1222.
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K, Kristensen L-E, Eriksson J, et al. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand J Rheumatol. 2015;44:431–437.
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Joensuu JT, Pirilä L, et al. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol. 2017;46:359–363.
   PubMed Web of Science ®Google Scholar
• Martínez-Santana V, González-Sarmiento E, Calleja-Hernández M, et al. Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Prefer Adherence. 2013;7:719–727.
   PubMed Web of Science ®Google Scholar
• Du Pan SM, Scherer A, Gabay C, et al. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71:997–999.
   PubMed Web of Science ®Google Scholar
• Leon L, Rodriguez-Rodriguez L, Rosales Z, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016;45:456–460.
   PubMed Web of Science ®Google Scholar
• Lee M-Y, Shin J-Y, Park S-Y, et al. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum. 2018;47:485–491.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Saxne T, Nilsson J-A, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22–32.
   PubMed Web of Science ®Google Scholar
• Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74:354–360.
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Favalli EG, Sangiorgi D, et al. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res. 2016;9:9–17.
   PubMed Web of Science ®Google Scholar
• Fisher A, Bassett K, Wright JM, et al. Comparative persistence of the TNF antagonists in rheumatoid arthritis–a population-based cohort study. PLoS One. 2014;9:e105193.
   PubMed Web of Science ®Google Scholar
• Salmon J-H, Letarouilly J-G, Goëb V, et al. Actual persistence of abatacept in rheumatoid arthritis: results of the French-Ric Network. J Clin Med. 2020;9:1528.
   Web of Science ®Google Scholar
• Takasugi K, Nishida K, Natsumeda M, et al. IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis. Mod Rheumatol. 2018;28:452–460.
   PubMed Web of Science ®Google Scholar
• Berthold E, Månsson B, Gullstrand B, et al. Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis. Scand J Rheumatol. 2018;47:22–26.
   PubMed Web of Science ®Google Scholar
• Benucci M, Grossi V, Manfredi M, et al. Laboratory monitoring of biological therapies in rheumatology: the role of immunogenicity. Ann Lab Med. 2020;40:101–113.
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1445–1452.
   PubMed Web of Science ®Google Scholar
• Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13:R105.
   PubMed Web of Science ®Google Scholar
• Lequerré T, Rottenberg P, Derambure C, et al. Predictors of treatment response in rheumatoid arthritis. Joint Bone Spine. 2019;86:151–158.
   PubMed Web of Science ®Google Scholar
• Mena-Vazquez N, Manrique-Arija S, Yunquera-Romero L, et al. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. Rheumatol Int. 2017;37:1709–1718.
   PubMed Web of Science ®Google Scholar
• Rodrigues JR, Faria DS, Neves JS, et al. Positive affect as a predictor of adherence in patients with rheumatoid arthritis. Acta Reumatol Port. 2019;44:132–137.
   PubMed Web of Science ®Google Scholar
• López-Medina C, Moltó A, Gérald F, et al. Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: results of a survey of 1594 patients. Joint Bone Spine. 2019;86:610–614.
   PubMed Web of Science ®Google Scholar
• Narongroeknawin P, Chevaisrakul P, Kasitanon N, et al. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: analysis from the Thai Rheumatic Disease Prior Authorization registry. Int J Rheum Dis. 2018;21:170–178.
   PubMed Web of Science ®Google Scholar
• Iannone F, Salaffi F, Fornaro M, et al. nfluence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis in real-world settings. Eur J Clin Invest. 2018;48(11):e13013.
   PubMed Web of Science ®Google Scholar